In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Pfizer Japan No Longer Disclosing Biosimilar Development Status for “Competitive Reasons”
February 23, 2018
- Sumitomo Dainippon’s iPSC-Based Parkinson’s Therapy Set for IIT Launch in FY2018
February 22, 2018
- Nippon Kayaku’s Novel Paclitaxel Form in Breast Cancer PII after PIII Miss
February 22, 2018
- Takeda, Wave Ink Antisense Pact for Neurological Diseases
February 22, 2018
- Novartis Japan Chief on Rare Paternity Leave, Looks to Lead by Example
February 22, 2018
- Bristol-Myers Japan Taps Ex-AZ Exec Hashigami as Development Chief
February 21, 2018
- Taniuchi Appointed as Santen President and COO
February 21, 2018
- Aducanumab Trial Tweak “Common Decision” to Boost Statistical Confidence: Biogen CEO
February 21, 2018
- Seikagaku to Run Add’l PIII for Lumbar Disc Herniation Drug in US
February 20, 2018
- Fujifilm Starts Japan PII for Radiopharmaceutical in Pheochromocytoma
February 20, 2018
- Dovobet Gel Wins Japan Approval: LEO/Kyowa Kirin
February 20, 2018
- Medical System Network Taps into Generic Business via Its Dispensing Pharmacy Chains, Aiming at Future Expansion
February 20, 2018
- Takeda’s Specialty Biz Unit Most Likely to Handle GI Meds, Entyvio Launch Apparently Eyed
February 20, 2018
- Takeda to Revamp Sales Offices as Japan Shifts to Community-Based Care System
February 20, 2018
- Lenvima OK’ed for UK Health Coverage in Thyroid Cancer
February 19, 2018
- Oncolys Invests in US Immuno-Oncology Startup
February 19, 2018
- Sumitomo Dainippon Halts Development of FXR Agonist in Japan, South Korea
February 16, 2018
- Daiichi Sankyo Files Mirogabalin in Japan for PNP
February 16, 2018
- Global Brands Drive Otsuka’s Pharma Sales in 2017
February 15, 2018
- Astellas Picks Up US Upstart, Grabs Full Access to Universal Donor Cell Technology
February 15, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…